

FORM PTO-1390
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371**

ALBRE 17

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

09/890654

INTERNATIONAL APPLICATION NO.

PCT/DE00/00330

INTERNATIONAL FILING DATE

28 JANUARY 2000

PRIORITY DATE CLAIMED

4 FEBRUARY 1999

TITLE OF INVENTION

METHOD FOR DETERMINING THE CONCENTRATION OF THROMBIN INHIBITORS

APPLICANT(S) FOR DO/EO/US

NOWAK, Gotz, et al.



AUG 03 2001

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR §1.5) 09/890654		INTERNATIONAL APPLICATION NO. PCT/DE00/00330		ATTORNEY'S DOCKET NUMBER ALBRE 17	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)): Search Report has been prepared by the EPO or JPO..... \$860.00 International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$690.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$710.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$1000.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C.F.R. §1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =	0	x \$ 18.00	\$0.00	
Independent claims	- 3 =	0	x \$ 80.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 270.00		
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
Reduction of 1/2 for filing by small entity, if applicable. Applicant qualifies.				(\$430.00)	
SUBTOTAL =				\$430.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.					
TOTAL FEES ENCLOSED =				\$430.00	
				Amount to be refunded:	
				charged:	
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$430.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>13-3402</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Customer Number 23,599					
 23599 PATENT TRADEMARK OFFICE			SIGNATURE  Anthony J. Zelano NAME		
Filed: 3 AUGUST 2001			27,969		
AJZ:kmo			REGISTRATION NUMBER		

09/890654

Rec'd PCT/PTO 05 NOV 2001

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/DE00/00330
International Filing Date : 28 JANUARY 2000
Priority Date(s) Claimed : 4 FEBRUARY 1999
Applicant(s) (DO/EO/US) : NOWAK, Gotz, et al.

Title: METHOD FOR DETERMINING THE CONCENTRATION OF THROMBIN INHIBITORS

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

3. (Amended) A method according to claim 1, wherein the coagulation inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., is selected from the group "calcium-complex forming agents, heparin, heparinoids, anti-thrombin III, protein C, fibrin polymerization inhibiting substances and mixtures of such substances".
4. (Amended) A method according to claim 1, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is selected from the group of the snake venoms or snake venom fractions.

5. (Amended) A method according to claim 1, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is ecarin.

6. (Amended) A method according to claim 1, wherein the chromogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., releases p-nitroanilin under dissociation, and the light absorption measurement is performed at 405 nm.

7. (Amended) A method according to claim 1, wherein in step c) a first absorption or emission measurement after 0 - 100 s, preferably 0 - 50, most preferably 5 - 15 s, and a second one after another 10 - 1,000 s, preferably 50 - 500s, most preferably 150 - 300 s, measured from the addition of the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., are performed.

8. (Amended) A method according to claim 1, wherein the thrombin inhibitor is hirudin, a hirulog or a synthetic thrombin inhibitor.

11. (Amended) A test kit according to claim 9, wherein the kit components are separated from each other but provided in a single test kit package.

12. (Amended) A test kit according to claim 9, wherein as an optional additional kit component, a solution with prothrombin is provided.

13. (Amended) Thrombin inhibitors, which are available by the following steps:

A) elements of a group of prospective thrombin inhibitors are submitted subsequently or separately and simultaneously in a given and preferably identical concentration to a method according to claim 2,

B) the reduction of the light absorption or light emission per time unit is determined for each prospective thrombin inhibitor and compared to the light absorption or light emission per time unit of a given, preferably identical concentration of hirudin determined under identical conditions,

C) those prospective thrombin inhibitors are selected the reduction of the light absorption or light emission of which per time unit corresponds to at least 10 % of the corresponding reduction when hirudin is used.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1

2200 Clarendon Boulevard, Suite 1400

Arlington, VA 22201

Direct Dial: 703-812-5311

Facsimile: 703-243-6410

Email: zelano@mwzb.com

AJZ:jmm

FILED: 5 NOVEMBER 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) A method according to claim 1 ~~or 2~~, wherein the coagulation inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., is selected from the group "calcium-complex forming agents, heparin, heparinoids, anti-thrombin III, protein C, fibrin polymerization inhibiting substances and mixtures of such substances".
4. (Amended) A method according to ~~one of~~ claims 1 ~~to 3~~, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is selected from the group of the snake venoms or snake venom fractions.
5. (Amended) A method according to ~~one of~~ claims 1 ~~to 4~~, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is ecarin.
6. (Amended) A method according to ~~one of~~ claims 1 ~~to 5~~, wherein the chromogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., releases p-nitroanilin under dissociation, and the light absorption measurement is performed at 405 nm.
7. (Amended) A method according to ~~one of~~ claims 1 ~~to 6~~, wherein in step c) a first absorption or emission measurement after 0 - 100 s, preferably 0 - 50, most preferably 5 - 15 s, and a second one after another 10 - 1,000 s, preferably 50 - 500s, most preferably 150 - 300 s, measured from the addition of the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., are performed.
8. (Amended) A method according to ~~one of~~ claims 1 ~~to 7~~, wherein the thrombin inhibitor is hirudin, a hirulog or a synthetic thrombin inhibitor.

11. (Amended) A test kit according to claim 9 ~~or 10~~, wherein the kit components are separated from each other but provided in a single test kit package.

12. (Amended) A test kit according to claim 9 ~~or 10~~, wherein as an optional additional kit component, a solution with prothrombin is provided.

13. (Amended) Thrombin inhibitors, which are available by the following steps:

- A) elements of a group of prospective thrombin inhibitors are submitted subsequently or separately and simultaneously in a given and preferably identical concentration to a method according to ~~one of~~ claims 2 ~~to 8~~,
- B) the reduction of the light absorption or light emission per time unit is determined for each prospective thrombin inhibitor and compared to the light absorption or light emission per time unit of a given, preferably identical concentration of hirudin determined under identical conditions,
- C) those prospective thrombin inhibitors are selected the reduction of the light absorption or light emission of which per time unit corresponds to at least 10 % of the corresponding reduction when hirudin is used.

Method for determining the concentration
of thrombin inhibitors

5

Specification

10 The invention relates to a method for determining the
concentration of thrombin inhibitors, wherein body liquid is
taken from a living body and wherein a substance separating
prothrombin into meizothrombin or meizothrombin-des
fragment 1 (in the following Mtdesfg1) is added to said
body liquid. - As thrombin inhibitors are understood all
natural or synthetic substances directly inhibiting thrombin
or initial thrombin products. An example for a natural
15 thrombin inhibitor is hirudin, extracted from the saliva of
hirudo medicinalis. Hirudin is a very small protein com-
posed of 65 amino acids and having a molecular weight of 7
kD. Examples for synthetic thrombin inhibitors are the so-
called hirulogs comprising partial sequences being analo-
20 gous or homologous to hirudin, and polypeptides composed
of or comprising a tripeptide Phe-Pro-Arg or derivatives of
such a tripeptide, such as boric acid derivatives, chlo-
romethylketon derivatives, benzamidine derivatives, argini-
nals, amino acid modified derivatives and the like. The
25 above substances have probably the same mechanism effects
as hirudin. As donors of the body liquid are possible human
beings and mammals, such as rodents. Examples for body
liquids are in particular blood or blood plasma produced
from blood. But other body liquids not containing pro-
30 thrombin are also possible, for instance urine, liquor, sa-
liva, peritoneal liquid and others. Then, according to the
invention, prothrombin is added. Non-turbid means that
there should be no substantial amounts of suspended parti-
cles in the body liquid to be examined. This can be
35 achieved, if necessary, by centrifugation of the body liquid
and separation of the remainder.

The theoretical background the invention is based on is
the following. The transformation of prothrombin into

thrombin is an essential factor for blood coagulation. Thrombin acts on the creation of fibrin monomers from fibrinogen and on the polymerization of the fibrin monomers. Prothrombin is transformed into thrombin with the contribution of activated factor X, activated factor V Ca⁺⁺ ions and phospholipids, such as platelet factor 3. A multi-step reaction takes place, with intermediates being formed in relatively small amounts. If however the coagulation is initiated by means of for instance ecarin or another snake venom or snake venom fraction, an "atypical" intermediate will be formed, such as meizothrombin, PIVKA meizothrombin or meizothrombin-des fragment 1 (PIVKA is the abbreviation for a protein being induced by a vitamin K antagonist). These atypical intermediates interestingly are inactivated for instance by hirudin, not however by heparin (factors IIa, IXa, XIa, XIIa inhibitor and/or antithrombin). Besides, they will also lead to thrombin formation and subsequently to coagulation. The affinity of hirudin and other synthetic thrombin inhibitors to the atypical intermediates is very high ($k_i > 10^{-10}$ mol/l for meizothrombin), so that the free atypical intermediate is temporarily bound by the thrombin inhibitor.

The above fundamentals are used in a method of the type referred to above, described in document US-A-5,547,850, wherein so to speak the consumption of the thrombin inhibitor is detected by measurement of the delay of coagulation. A large amount of thrombin inhibitor will lead to a long time before the beginning of coagulation, and vice versa. In principle, this method has proven successful in practical applications. The drawbacks however are that in cases of reduced fibrinogen level, falsifications may occur, since a (too) low fibrinogen level, same as a high thrombin inhibitor level, may lead to long coagulation times.

The invention is based on the technical object to specify a method for determining the concentration of thrombin inhibitors, said method providing precise values independently from the fibrinogen level.

For achieving this object, the invention teaches a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following steps: a) the
5 body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary, b) to the non-turbid body liquid obtained in step a) are added a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or
10 Mtdesfgl, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., and as an option prothrombin, c) the solution or mixture, resp., obtained in step b) is subjected to a
15 wavelength-selective light absorption or light emission measurement as a function of the time, d) from the reduction of the light absorption or light emission in step c) per time unit is determined the amount of the thrombin inhibitor included in the body liquid by comparison to previously
20 determined standard curves. Alternatively to the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., or as a complement hereto, meizothrombin or Mtdesfgl, resp., may be added. Further, the invention teaches a method for determining the (specific) activity of
25 thrombin inhibitors (for inhibiting generated meizothrombin or Mtdesfgl, resp.) in a non-turbid aqueous liquid, comprising the following steps: a) a body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary, or a non-turbid liquid
30 is synthetically produced, b) to the non-turbid body liquid obtained in step a) are added a given amount of thrombin inhibitor, if applicable a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., a chromogenic or fluoro-
35 genic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., or meizothrombin or

Mt desfgl, resp., and as an option prothrombin, c) the solution or mixture, resp., obtained in step b) is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time, d) from the reduction of the light absorption or light emission in step c) per time unit is determined the activity of the thrombin inhibitor by comparison (of the negative slope) to previously determined standard curves. - As chromogenic substrates are designated substances containing chromophoric groups and being specifically dissociated by thrombin, resulting in a coloration. Fluorogenic substances are substances that are specifically dissociated by thrombin, resulting in fluorescent substances. Prothrombin may be added, if the body liquid does not naturally contain sufficient prothrombin, for instance in the case of vitamin K deficiency, or if the amount of thrombin inhibitor to be expected or the activity of the thrombin inhibitor will recommend so, or if during an illness a prothrombin deficiency has occurred.

The invention is based on the surprising detection that chromogenic or fluorogenic substances being specifically dissociated by thrombin are equally specifically dissociable by meizothrombin or Mt desfgl, resp. This could not be expected since intermediates are necessary pre-steps, however do not naturally develop the same effects or reactivities as the thrombin. By that the detecting reaction according to the invention exclusively takes place by monitoring the meizothrombin or Mt desfgl inhibition, resp., by means of a color reaction, the detection is completely independent from the fibrinogen level. Rather, for body liquids, in particular blood or blood plasma, the coagulation has even to be prevented, in order to not disturb the color reaction evaluation. In addition, the determination of the concentration of the thrombin inhibitors is in all sections at least as accurate as the determination by means of the prior art method at a high fibrinogen level. Also, there is independence from any orally administered anti-coagulants possibly included in the liquid. Further advantages are: quick measurement within

minutes in chromogenic channels of conventional automatic coagulation devices (these often measure a turbidity at several wavelengths for the purpose of correction and therefore usually offer the possibility of the wavelength-selective and wavelength-variable light absorption measurement); high reproducibility of the found values because of very little variations of the individual values (the confidence interval is according to a multitude of test series below 5 %, usually 2.2 - 3.5 %); the high accuracy or reproducibility is further also achieved at very high thrombin inhibitor or hirudin levels, resp.; due to above features the method according to the invention is suitable for national and international standardization.

The method according to the invention is used on one hand in science, namely in all areas of examinations where concentrations of thrombin inhibitor have to be determined, and for the (if applicable, high-capacity) screening of prospective thrombin inhibitors. In the latter case, a multitude of synthetic prospective inhibitors can be examined with a high throughput with regard to their actual effects. Activity means here the determination whether at all an inhibition takes place, and if yes, how the kinetics or the specific activity are. On the other hand, clinical application is also a issue, for instance for monitoring the thrombin inhibitor levels of patients to whom the inhibitor is administered for therapeutical reasons. Thus it can be prevented, in a simple and economical way, that an under or over-dosage of the thrombin inhibitor takes place, and that in quasi-continuous or discontinuous monitoring.

In detail, the substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., may be selected from the group "calcium-complex forming agents, heparin, heparinoids, anti-thrombin III, protein C, fibrin polymerization inhibiting substances and mixtures of such substances". A specific example for this is Pefabloc FG manufactured by Pentapharm A; Bale, Switzerland, this substance being a tetrapeptide (Gly-Pro-Arg-Pro)

and preventing the fibrinogen polymerization with a high affinity. The substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., may be selected from the group of the snake venoms or snake venom fractions, for instance venoms of dispholidus, rhabdophis, bothrops, notechis, oxyuranus and Russel's vipers. Suitably cleaned fractions therefrom are used. Preferably, ecarin, a highly cleaned fraction of the echis-carinatus toxin, or multi-squamase, the prothrombin dissociating enzyme from echis multi-squamatus, is used. Such substances as for instance ecarin are commercially available from Pentapharm AG, Switzerland, among other sources.

The chromogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., may release p-nitroaniline under dissociation, and the light absorption measurement can then be performed at 405 nm. Examples for such or even other substrates are tripeptides available under the names Chromozym TH or Pefachrom TH from the companies Chromogenix, Boehringer, Pentapharm (Pefachrome TH is H-D-ChG-Ala-Arg-pN.2AcOH). An example for fluorochromic substrates is Pefachrom TH fluorogen, being available under the name Pefa 15865 from the company Pentapharm.

In detail, it is recommended for the activities in question to perform in step c) a first absorption or emission measurement after 0 - 100 s, preferably 0 - 50, most preferably 5 - 15 s, and a second one after another 10 - 1,000 s, preferably 50 - 500s, most preferably 150 - 300 s, measured from the addition of the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp. The method according to the invention is particularly suited for the determination of hirudin or the determination of the concentration and/or the activity of synthetic thrombin inhibitors or hirulogs.

The invention also relates to a test kit for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid,

comprising the following kit components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., and K3) a solution of a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., wherein component K3) may be replaced or complemented by a component K3a) of a solution with meizothrombin or Mtdesfgl, resp., and a test kit for determining the activity of thrombin inhibitors in a non-turbid body or in a non-turbid extract from a body liquid or in a non-turbid non-natural aqueous liquid, comprising the following kit components: as an option K1) a solution of a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., and K3) a solution of a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., wherein component K3) may be replaced or complemented by a component K3a) of a solution with meizothrombin or Mtdesfgl, resp. The kit components may be separated from each other or provided in a single test kit package. Further, as an optional additional kit component, a solution with prothrombin may be provided.

In any case it is understood that for the addition of substances dissociating thrombin, meizothrombin or Mtdesfgl, resp., and/or meizothrombin or Mtdesfgl, resp., these are used in defined, given amounts. Corresponding considerations apply to the substrate.

Based on the method according to the invention and being particularly well suited for screening purposes, further subject matter of the invention are thereby found or characterized new thrombin inhibitors, which are namely available by the following steps: A) elements of a group of prospective thrombin inhibitors are submitted subsequently or separately and simultaneously in a given and preferably

identical concentration to a method according to one of claims 2 to 8, B) the reduction of the light absorption or light emission per time unit is determined for each prospective thrombin inhibitor and compared to the light absorption or light emission per time unit of a given, preferably identical concentration of hirudin determined under identical conditions, C) those prospective thrombin inhibitors are selected the reduction of the light absorption or light emission of which per time unit corresponds to at least 10 % of the corresponding reduction when hirudin is used.

For the test kit according to the invention and the thrombin inhibitors found according to the invention apply the detailed explanations as given above for the method according to the invention.

As far as meizothrombin or Mtdesfgl, resp., is used, this can commercially be bought, for instance from Pentapharm AG, Switzerland, can however also be produced at immobilized ecarin according to the statement in document US-A-5,547,850.

The devices to be used for the invention are for instance semi or fully automatic coagulation devices being present anyway. These may for instance be automatic coagulation analyzers of the type Sysmex CA-500 or S2000 of the company Dade-Behring or of the type Electra 2000. In the CA-500, the light emitted by a LED is sent through a filter (405 nm) and then through the sample. The CA-500 determines in the chromogenic channel the variation or reduction of the light absorption of dyes, as for instance pNA (p-nitroaniline). If there is for instance hirudin in a sample, the generated or added meizothrombin or Mtdesfgl, resp., is inactivated, with the consequence of a thereby inhibited pNA release. The as such differently behaving (changing) optical density of the sample is recorded by a photodiode, and is evaluated. The monitored change in the light absorption is inversely proportional to the hirudin activity.

In the following, the invention will be explained in more detail, based on experiments representing examples of execution only.

For the determination of a standard curve, pooled human citrate plasma was treated with given amounts of hirudin solution. The thus obtained standard solutions were measured in a CA-500.

As reagents were filled in:

Reagent 1 [inhib] (room temperature): 400 μ l Pefabloc FG (20 mM; dissolved in 0.9 % NaCl) + 2,100 μ l Tris buffer;

Reagent 2 [chromo] (room temperature): Pefachrome TH (10 μ mol/vial), diluted to 3 μ mol/ml aq. dest,

Reagent 3 [ecarin] (15 °C): ecarin (50 EU/vial), diluted to .3 EU/ml (the contents of the ecarin bottle are dissolved in 5 ml of 0.9 % NaCl solution and shortly prior to application set to the final concentration with a 1:2 mixture of 0.9 % NaCl, containing 1 % Prionex (Merck) and 0.1 M CaCl_2 solution.

The test records are shown below. As dil. buffer was used a mixture of 16.6 μ l prothrombin (cleaned; protein content 2.22 mg/ml) and 984 μ l of a mixture of 900 μ l Tris buffer (0.05 M, pH 8, 37 °C, + 0.1 M NaCl) and 100 μ l Prionex (Merck).

Test records		Name	Ecch
		Detector	Chrome
		Start Point	5 sec
		End Point	180 sec
		Sensitivity	Low Gain
	1 Sample Vol.	Citrate plasma	5 μ l
	Dil. Vol.	Buffer	70 μ l
	2 Sample Vol.		0 μ l
	*****		0 μ l
	Reagent 1		30 sec
	Reag. Vol.	Inhib	125 μ l

<u>Rinse</u>		<u>125 μl</u>
Reagent 2		120 sec
Chromo	Chromo	20 μ l
<u>Rinse</u>		<u>100 μl</u>
Reagent 3		210 sec
Reag. Vol.	Ecarin	20 μ l
<u>Rinse</u>		<u>50 μl</u>

(Rinse: 1 % sodium hypochlorite solution)

Fig. 1 shows the obtained standard curve. The extremely good correlation coefficient of 0.9977 is conspicuous. In the experiment, just replace the standard sample by the sample to be determined, and read the unknown hirudin concentration in Fig. 1 from the measured reduction of the optical density.

PATENT CLAIMS

5 1. A method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following steps:

10 a) the body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary,

15 b) to the non-turbid body liquid obtained in step a) are added a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., and as an option prothrombin,

20 c) the solution or mixture, resp., obtained in step b) is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time,

25 d) from the reduction of the light absorption or light emission in step c) per time unit is determined the amount of the thrombin inhibitor included in the body liquid by comparison to previously determined standard curves.

2. A method for determining the activity of thrombin inhibitors in a non-turbid aqueous liquid, comprising the following steps:

30 a) a body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary, or a non-turbid liquid is synthetically produced,

b) to the non-turbid body liquid obtained in step a) are added a given amount of thrombin inhibitor, if applicable a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., or meizothrombin or Mtdesfgl, resp., and as an option prothrombin,

c) the solution or mixture, resp., obtained in step b) is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time,

d) from the reduction of the light absorption or light emission in step c) per time unit is determined the activity of the thrombin inhibitor by comparison to previously determined standard curves.

3. A method according to claim 1 or 2, wherein the coagulation inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., is selected from the group "calcium-complex forming agents, heparin, heparinoids, anti-thrombin III, protein C, fibrin polymerization inhibiting substances and mixtures of such substances".

4. A method according to one of claims 1 to 3, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is selected from the group of the snake venoms or snake venom fractions.

5. A method according to one of claims 1 to 4, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is ecarin.

6. A method according to one of claims 1 to 5, wherein the chromogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., releases p-nitroanilin under dissociation, and the light absorption measurement is performed at 405 nm.

7. A method according to one of claims 1 to 6, wherein in step c) a first absorption or emission measurement after 0 - 100 s, preferably 0 - 50, most preferably 5 - 15 s, and a second one after another 10 - 1,000 s, preferably 50 - 500s, most preferably 150 - 300 s, measured from the addition of the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., are performed.

8. A method according to one of claims 1 to 7, wherein the thrombin inhibitor is hirudin, a hirulog or a synthetic thrombin inhibitor.

9. A test kit for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following kit components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., and K3) a solution of a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., wherein component K3) may be replaced or complemented by a component K3a) of a solution with meizothrombin or Mtdesfgl, resp.

10. A test kit for determining the activity of thrombin inhibitors in a non-turbid body or in a non-turbid extract from a body liquid or in a non-turbid non-natural aqueous liquid, comprising the following kit components: as an op-

tion K1) a solution of a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., and K3) a solution of a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., wherein component K3) may be replaced or complemented by a component K3a) of a solution with meizothrombin or Mtdesfgl, resp.

11. A test kit according to claim 9 or 10, wherein the kit components are separated from each other but provided in a single test kit package.

12. A test kit according to claim 9 or 10, wherein as an optional additional kit component, a solution with prothrombin is provided.

13. Thrombin inhibitors, which are available by the following steps:

A) elements of a group of prospective thrombin inhibitors are submitted subsequently or separately and simultaneously in a given and preferably identical concentration to a method according to one of claims 2 to 8,

B) the reduction of the light absorption or light emission per time unit is determined for each prospective thrombin inhibitor and compared to the light absorption or light emission per time unit of a given, preferably identical concentration of hirudin determined under identical conditions,

C) those prospective thrombin inhibitors are selected the reduction of the light absorption or light emission of which per time unit corresponds to at least 10 % of the corresponding reduction when hirudin is used.

Fig. 1

Hirudin concentration ($\mu\text{g/ml}$ plasma)

099054-10501
10501-099054

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR DETERMINING THE CONCENTRATION OF THROMBIN INHIBITORS

the specification of which

☐ is attached hereto

☒ was filed on 28 JANUARY 2000 as United States Application Number or PCT International Application Number PCT/DE00/00330 and (if applicable) was amended on _____

I hereby authorize our attorneys to insert the serial number assigned to this application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 USC §119			
APPLICATION NO.	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
199 04 674.3	GERMANY	4 FEBRUARY 1999	YES

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. §119(e)	
APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under 35 U.S.C. §120 of any United States application, or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PRIOR U.S./PCT INTERNATIONAL APPLICATION(S) DESIGNATED FOR BENEFIT UNDER 37 U.S.C. §120		
APPLICATION NO.	FILING DATE	STATUS — PATENTED, PENDING, ABANDONED

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith: I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E.J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Richard J. Traverso (30,595); John A. Sopp (33,103); Richard M. Lebovitz (37,067); John H. Thomas (33,460); Catherine M. Joyce (40,668); Nancy J. Axelrod (44,014); James T. Moore (35,619); James E. Ruland (37,432); Jennifer J. Branigan (40,921) and Robert E. McCarthy (46,044)





Send Correspondence to Customer Number 23599



23599

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of sole or first inventor (given name, family name) Gotz NOWAK	
Signature 	Date 15.08.2001
Residence Jena Germany	Citizenship Germany
Post Office Address Ziegesaustrasse 1, D-07747 Jena, Germany 	
Full Name of additional joint inventor (given name, family name) Eike BUCHA	
Signature 	Date 13.08.2001
Residence Erfurt, Germany	Citizenship Germany
Post Office Address Kirchberg 9, D-99094 Erfurt, Germany 	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	

☐ Additional joint inventors are named on separately numbered sheets attached hereto.